These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 24962903)

  • 21. Effects of Fecal Microbiota Transplantation on Composition in Mice with CKD.
    Barba C; Soulage CO; Caggiano G; Glorieux G; Fouque D; Koppe L
    Toxins (Basel); 2020 Nov; 12(12):. PubMed ID: 33255454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Impact of CKD on Uremic Toxins and Gut Microbiota.
    Rysz J; Franczyk B; Ławiński J; Olszewski R; Ciałkowska-Rysz A; Gluba-Brzózka A
    Toxins (Basel); 2021 Mar; 13(4):. PubMed ID: 33807343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Uremic Solute-Aryl Hydrocarbon Receptor-Tissue Factor Axis Associates with Thrombosis after Vascular Injury in Humans.
    Kolachalama VB; Shashar M; Alousi F; Shivanna S; Rijal K; Belghasem ME; Walker J; Matsuura S; Chang GH; Gibson CM; Dember LM; Francis JM; Ravid K; Chitalia VC
    J Am Soc Nephrol; 2018 Mar; 29(3):1063-1072. PubMed ID: 29343519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Uremic Toxins from the Gut Microbiota on Bone: A Brief Look at Chronic Kidney Disease.
    Black AP; Cardozo LF; Mafra D
    Ther Apher Dial; 2015 Oct; 19(5):436-40. PubMed ID: 25944654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contribution of Gut Microbiota-Derived Uremic Toxins to the Cardiovascular System Mineralization.
    Filipska I; Winiarska A; Knysak M; Stompór T
    Toxins (Basel); 2021 Apr; 13(4):. PubMed ID: 33920096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of uremic toxins on vascular and bone remodeling.
    Barreto FC; Barreto DV; Liabeuf S; Drüeke TB; Massy ZA
    Semin Dial; 2009; 22(4):433-7. PubMed ID: 19708996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients.
    Ando M; Iwata A; Ozeki Y; Tsuchiya K; Akiba T; Nihei H
    Kidney Int; 2002 Nov; 62(5):1757-63. PubMed ID: 12371977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimized metabolomic approach to identify uremic solutes in plasma of stage 3-4 chronic kidney disease patients.
    Mutsaers HA; Engelke UF; Wilmer MJ; Wetzels JF; Wevers RA; van den Heuvel LP; Hoenderop JG; Masereeuw R
    PLoS One; 2013; 8(8):e71199. PubMed ID: 23936492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erythropoietin does not modify the prothrombotic effect induced by uremic media on endothelial cells.
    Fusté B; Díaz-Ricart M; Cases A; López-Pedret J; Ordinas A; Escolar G
    Haematologica; 2002 Sep; 87(9):1006-8. PubMed ID: 12217816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uraemic solutes as therapeutic targets in CKD-associated cardiovascular disease.
    Ravid JD; Kamel MH; Chitalia VC
    Nat Rev Nephrol; 2021 Jun; 17(6):402-416. PubMed ID: 33758363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombotic Role of Blood and Endothelial Cells in Uremia through Phosphatidylserine Exposure and Microparticle Release.
    Gao C; Xie R; Yu C; Ma R; Dong W; Meng H; Zhang Y; Si Y; Zhang Z; Novakovic V; Zhang Y; Kou J; Bi Y; Li B; Xie R; Gilbert GE; Zhou J; Shi J
    PLoS One; 2015; 10(11):e0142835. PubMed ID: 26580207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic Abnormalities in Diabetes and Kidney Disease: Role of Uremic Toxins.
    Koppe L; Fouque D; Soulage CO
    Curr Diab Rep; 2018 Sep; 18(10):97. PubMed ID: 30194541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From the gastrointestinal tract (GIT) to the kidneys: live bacterial cultures (probiotics) mediating reductions of uremic toxin levels via free radical signaling.
    Vitetta L; Linnane AW; Gobe GC
    Toxins (Basel); 2013 Nov; 5(11):2042-57. PubMed ID: 24212182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease.
    Gryp T; De Paepe K; Vanholder R; Kerckhof FM; Van Biesen W; Van de Wiele T; Verbeke F; Speeckaert M; Joossens M; Couttenye MM; Vaneechoutte M; Glorieux G
    Kidney Int; 2020 Jun; 97(6):1230-1242. PubMed ID: 32317112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular mechanisms underlying uremic toxin-related systemic disorders in chronic kidney disease: focused on β
    Yamamoto S
    Clin Exp Nephrol; 2019 Feb; 23(2):151-157. PubMed ID: 29869756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Uremic Toxicity and Bone in CKD.
    Yamamoto S; Fukagawa M
    J Nephrol; 2017 Oct; 30(5):623-627. PubMed ID: 28573386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disposition and clinical implications of protein-bound uremic toxins.
    Jansen J; Jankowski J; Gajjala PR; Wetzels JFM; Masereeuw R
    Clin Sci (Lond); 2017 Jul; 131(14):1631-1647. PubMed ID: 28667064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does uremia cause vascular dysfunction?
    Brunet P; Gondouin B; Duval-Sabatier A; Dou L; Cerini C; Dignat-George F; Jourde-Chiche N; Argiles A; Burtey S
    Kidney Blood Press Res; 2011; 34(4):284-90. PubMed ID: 21691132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impaired muscle mitochondrial energetics is associated with uremic metabolite accumulation in chronic kidney disease.
    Thome T; Kumar RA; Burke SK; Khattri RB; Salyers ZR; Kelley RC; Coleman MD; Christou DD; Hepple RT; Scali ST; Ferreira LF; Ryan TE
    JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitochondria as a Source and a Target for Uremic Toxins.
    Popkov VA; Silachev DN; Zalevsky AO; Zorov DB; Plotnikov EY
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.